AGRX News and Press, Agile Therapeutics Inc. From 05/02/19

Agile Therapeutics (NASDAQ: AGRX ): Q1 GAAP EPS of -$0.13  misses by $0.03 . More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Company Plans to Resubmit Twirla® NDA in Second Quarter of 2019 Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 PRINCETON, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today rep...

PRINCETON, N.J., March 28, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the H.C. Wainwright Global Life Sciences conference on Monday April 8, 2019 a...

PRINCETON, N.J., March 15, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a women's healthcare company, today announced that an abstract presenting data from two Phase 1 in vivo wear studies on the adhesion of Twirla ® has been selected for a poster presentation du...

Agile Therapeutics (NASDAQ: AGRX ): Q4 GAAP EPS of -$0.11 beats by $0.04. Cash and cash equivalents of $7.8M Press Release More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 Company plans to resubmit Twirla NDA in second quarter of 2019 PRINCETON, N.J., March 12, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reporte...

PRINCETON, N.J., March 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Senior Vice President and Chief Financial Officer, Scott Coiante will present at Oppenheimer’s 29 th Annual Healthcare Conference on Tu...

Thinly traded nano cap Agile Therapeutics ( AGRX +20.8% ) is up on a 7x surge in volume on the heels of its private placemen t of ~8.4M shares of common stock at $0.93 per share yielding gross proceeds of ~$7.8M. More news on: Agile Therapeutics, Inc., Healthcare stocks news, Stocks on ...

PRINCETON, N.J., March 04, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced today that it has entered into a definitive stock purchase agreement with Perceptive Advisors, LLC, for the private placement of approximately 8.4 mill...

On February 11 th , Agile Therapeutics ( AGRX ) reported topline results from their comparative wear study challenging the adhesion of Twirla matched against Xulane (Figure 1). Once the news hit the wire, AGRX quickly traded up above $1.00 in the premarket but was quickly hit with selling ...